ArticleJournal of translational medicine2026
ENO1 interacts with PKM to promote HBV-related hepatocellular carcinoma progression and HBV replication.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe progression of hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC) is driven by complex interactions between metabolic reprogramming and viral replication. Glycolytic enzymes, including α-enolase (ENO1) and pyruvate kinase M (PKM), play key roles in tumor progression, but their specific contribution to HBV-associated HCC remains inadequately defined. This study investigates the molecular mechanisms by which ENO1 and PKM promote HCC progression and HBV replication.
methodsThe expression levels of ENO1 and PKM in HBV-infected HCC cells were evaluated, and their interaction was explored using co-immunoprecipitation (Co-IP), quantitative reverse transcription polymerase chain reaction (qRT-PCR), and Western blot analysis. Additionally, an HCC mouse model was employed to assess the impact of this interaction on HCC progression and HBV replication.
resultsBoth ENO1 and PKM were significantly upregulated in HBV-associated HCC cells and mouse models. Co-IP assays revealed a direct interaction between ENO1 and PKM. Functionally, ENO1 enhanced HCC cell proliferation, migration, invasion and in vivo tumor growth. Furthermore, elevated levels of ENO1 and PKM significantly increased HBV replication, thus exacerbating HCC progression.
conclusionsThis study indicated a novel mechanism in which ENO1 interacts with PKM to accelerate both HBV-related HCC progression and viral replication. These findings suggest that targeting the ENO1-PKM axis may provide a promising metabolic therapeutic approach for HBV-associated HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.